Kida K, Matsuda H
Jpn J Antibiot. 1985 Oct;38(10):2970-6.
Ceftizoxime suppositories (CZX-S) were given to 5 children comprising 3 with acute bronchitis, 1 with acute bronchitis complicated by enteritis, and 1 with acute urinary tract infection, in doses of 12.5 12.5-17.4 mg/kg with 1 suppository containing 125 mg or 250 mg (potency) given 3 times a day. The clinical response was "markedly effective" in 2 and "effective" in 3. Microbiologically CZX-S caused a eradication of 1 strain each of S. aureus and E. coli and caused a decrease of organisms in 1 strain of S. aureus. There were no adverse reactions or abnormal laboratory test findings attributable to CZX-S. In conclusion, CZX-S proved to be a clinically useful antibiotic preparation for the treatment of infection in children not suited to treatment with oral or intravenous preparations.
给5名儿童使用了头孢唑肟栓剂（CZX-S），其中3名患有急性支气管炎，1名患有急性支气管炎并发肠炎，1名患有急性尿路感染，剂量为12.5 - 17.4mg/kg，每次1粒栓剂含125mg或250mg（效价），每日给药3次。临床疗效为2例“显效”，3例“有效”。微生物学上，CZX-S使金黄色葡萄球菌和大肠杆菌各1株被清除，并使1株金黄色葡萄球菌中的细菌数量减少。未发现因CZX-S引起的不良反应或实验室检查异常结果。总之，CZX-S被证明是一种临床上有用的抗生素制剂，可用于治疗不适合口服或静脉制剂治疗的儿童感染。
